<DOC>
	<DOCNO>NCT01184898</DOCNO>
	<brief_summary>The purpose study evaluate addition Sirolimus ( rapamycin ) standard chemotherapy treatment patient high risk acute myelogenous leukemia ( AML ) . Cancer cell take patient studied laboratory see rapamycin affect mTOR pathway cell effect correlate well patient respond therapy .</brief_summary>
	<brief_title>Pilot Trial Sirolimus/MEC High Risk Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Recent improvement understand leukemia biology lead introduction highly effective , molecularly target therapy . This exemplified development BCR-ABL tyrosine kinase inhibitor imatinib monotherapy chronic myeloid leukemia ( CML ) combination chemotherapy BCR-ABL+ acute lymphoblastic leukemia ( ALL ) . Imatinib mesylate block protein make BCR-ABL oncogene . The PI3K ( phosphatidylinositol 3-kinases ) signal critical leukemia cell survival target . Growth survival stimulate signal transduction pathway abnormally universally activate AML ( Acute Myeloid Leukemia ) . This signal cascade think contribute survival growth tumor cell via downstream effect upon target protein AKT/Protein kinase B mammalian target rapamycin ( mTOR ) protein help control several cell function . In AML , others show PI3K signal constitutively activate 85 % primary sample small molecule PI3K inhibitor LY294002 cytotoxic vitro virtually sample test . As LY294002 poorly suit drug development , concentrate upon way inhibit signal transduction pathway . Mammalian target rapamycin ( mTOR ) emerge reasonable target due availability clinically available , highly specific inhibitor favorable safety profile . Mammalian target rapamycin ( mTOR ) play central complex role cancer cell ' metabolic regulation survival . This serine/threonine kinase coordinate several important cellular function activity modulate response amino acid , glucose , oxygen , ATP availability well extracellular growth factor ligation . Mammalian target rapamycin ( mTOR ) activity regulate protein translation , nutrient amino acid uptake , mitochondrial respiration , glycolysis , cell size regulation , cell cycle entry progression , ribosome biogenesis , autophagy . Constitutive mammalian target rapamycin ( mTOR ) activation commonly see cancer cell think promote survival set wide variety cellular insult . Importantly , mTOR open may cause chemotherapy resistance . Although regulation mTOR signal leukemia occur several input , mTOR activity AML think primarily regulate PI3K signal AKT via agent tumor suppressor tuberous sclerosis complex ( TSC1 &amp; 2 ) target rheb GTPase . Taken together , mammalian target rapamycin mTOR smart target molecularly target therapy AML due importance growth survival AML cell , necessity AML cell survival certain context , probable role chemotherapy resistance relapse .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients must histologic evidence high risk acute myeloid leukemia define one following : 1 . Primary refractory nonM3 AML ( ) Residual leukemia minimum 2 prior course chemotherapy ( Same different ) ( ii ) Evidence leukemia nadir bone marrow biopsy demonstrate evidence residual leukemia . 2 . Relapsed nonM3 AML 3 . Any nonM3 AML age &gt; 60 evidence favorable karyotype ( stratum 2 ONLY ) , define presence ( 8 ; 21 ) ( q22 ; q22 ) [ AML1ETO ] , inv16 ( p13 ; q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) [ CBF ; MYH11 ] cytogenetics , FISH , RTPCR 4 . Secondary AML ( antecedent hematologic malignancy follow therapy radiation chemotherapy another disease ) evidence favorable karyotype ( stratum 2 ONLY ) , define presence ( 8 ; 21 ) ( q22 ; q22 ) [ AML1ETO ] , inv16 ( p13 ; q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) [ CBF ; MYH11 ] cytogenetics , FISH , RTPCR Age &gt; = 18 ECOG = 0 1 Subjects FAB M3 ( ( 15 ; 17 ) ( q22 ; q21 ) [ PMLRAR ] ) eligible Subjects take follow eligible : Carbamazepine ( e.g. , Tegretol ) Rifabutin ( e.g. , Mycobutin ) Rifampin ( e.g. , Rifadin ) Rifapentine ( e.g. , Priftin ) St. John 's wort Clarithromycin ( e.g. , Biaxin ) Cyclosporine ( e.g . Neoral Sandimmune ) Diltiazem ( e.g. , Cardizem ) Erythromycin ( e.g. , AkneMycin , EryTab ) Itraconazole ( e.g. , Sporanox ) Ketoconazole ( e.g. , Nizoral ) Telithromycin ( e.g. , Ketek ) Verapamil ( e.g. , Calan SR , Isoptin , Verelan ) Voriconazole ( e.g. , VFEND ) Tacrolimus ( e.g . Prograf ) Subjects take fluconazole , voriconazole , itraconazole , posaconazole , ketoconazole within 72 hour study entry eligible . Reinstitution fluconazole , voriconazole , itraconazole , posaconazole , ketoconazole diltiazem permissible 72 hour last dose sirolimus . Subjects must receive chemotherapy agent ( except Hydroxyurea ) . Intrathecal methotrexate cytarabine permissible Subjects must receive growth factor , except erythropoietin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>mTOR</keyword>
	<keyword>rapamycin</keyword>
</DOC>